ArticleFrontiers in pharmacology2026
A computational pharmacokinetic-pharmacodynamic framework for simulating and comparing individualized levodopa dosing in Parkinson's disease.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease is associated with substantial inter-patient variability in motor response to levodopa therapy, making long-term dose selection and scheduling challenging. Computational modeling provides a systematic approach for investigating how pharmacokinetic and pharmacodynamic variability may influence treatment outcomes. This study presents a computational pharmacokinetic-pharmacodynamic framework for simulating and comparing individualized levodopa dosing strategies in Parkinson's disease. The framework integrates multi-compartment drug disposition, effect-site dynamics, and a nonlinear exposure-response relationship, using parameter ranges derived from published clinical and modeling studies. A heterogeneous virtual cohort was generated to represent variability in absorption, clearance, distribution, and pharmacodynamic sensitivity, and simulation-based optimization was applied to evaluate the effects of dose size, dosing interval, and timing across representative patient scenarios. Simulations demonstrated how alternative dosing schedules influence effect-site exposure stability and predicted therapeutic response patterns under inter-patient variability. Sensitivity analysis further identified key parameters contributing most strongly to simulated exposure-response behavior. Rather than providing prescriptive clinical recommendations, the proposed framework serves as an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.